pharmaphorum

JUNE 15, 2022

The 2nd NSCLC Drug Development Summit returns for its second year to unite biopharma and academic leaders during an exciting era of personalized medicine. Improve your drug development rationale across all lines of NSCLC and address challenges when moving therapies forward. Progress sequencing and combination approaches.

Drug Development 105

Drug Development Immunity Immunization 105

STAT

MAY 22, 2024

Startlingly effective shots quickly helped immunize a large portion of the population — at least initially, and in high-income countries. During the Covid-19 pandemic, vaccines were the main line of defense. Antiviral treatments were not as impactful.

Vaccines 336

Vaccines Immunity Immunization Drug Development 336

STAT

APRIL 10, 2024

The promise has long been an affordable, personalized cancer vaccine that could train the immune system to recognize proteins from cancer cells and, subsequently, destroy the tumor.

Vaccines 363

Vaccines Immunity Immunization Drug Development 363

STAT

DECEMBER 22, 2022

Sepsis, a deadly overreaction of the immune system to infection, has befuddled clinicians and researchers for decades. Covid-19 made things worse.

Immunity 334

Immunity Immunization Drug Development 334

Outsourcing Pharma

DECEMBER 21, 2020

A partnership between Immunai and 10x Genomics will use artificial intelligence to create a map of the immune system to help accelerate drug development.

Immunity 92

Immunity Immunization Drug Development 92

STAT

SEPTEMBER 26, 2023

Results released Tuesday from an early study of an autoimmune disease drug from Roivant Sciences’ Immunovant showed the treatment could reduce the levels of a key immune marker in the blood, a promising signal.

Immunity 336

Immunity Immunization Drug Development 336

Pharmaceutical Technology

APRIL 10, 2023

Aviceda Therapeutics (Aviceda) has entered into a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (QUB) for the development of next-generation glyco-immune therapeutics. The company strengthens the translational research collaboration between the US and Ireland.

Immunity 103

Immunity Immunization Drug Development 103

STAT

MARCH 28, 2024

Today, we’re reading about the world’s costliest drug, plus we learn about immune senescence and a potential cause for a kidney autoimmune disease. Sign up to get it in your inbox here. It’s Meghana. Read the rest…

Immunity 269

Immunity Immunization Drug Pricing Drug Development 269

pharmaphorum

NOVEMBER 1, 2024

The 8th Antigen-Specific Immune Tolerance Drug Development Summit is an event organised by Hanson Wade. Discover the latest developments and networking opportunities at this leading industry conference.

Immunity 52

Immunity Immunization Drug Development 52

BioPharma Dive

JUNE 20, 2023

The deal adds to recent M&A activity as well as signals pharma’s continued interest in pills for inflammatory conditions, which are meant to approach the potency of injectable therapies.

Immunity 95

Immunity Immunization Drug Development 95

STAT

NOVEMBER 28, 2023

The negative study, called ADVANCE-SC, was the second of two clinical trials involving the Argenx drug called efgartigimod in patients with primary immune thrombocytopenia (ITP), a debilitating condition that destroys blood-clotting platelets. Argenx shares were down 12% in early trading.

Immunity 291

Immunity Immunization Drug Development 291

BioPharma Dive

MARCH 25, 2024

Worth about $138 million upfront, the deal is another example of pharma interest in new drugs for inflammatory conditions like Crohn’s.

Immunity 69

Immunity Immunization Drug Development 69

World Pharma News

MAY 23, 2023

Jude Children’s Research Hospital and the University of Texas Southwestern Medical Center studied the structure and function of a transporter involved in cancer and immunity. The findings, published in Cell, have implications for drug development.

Drug Development 81

Drug Development Immunity Immunization Hospitals 81

STAT

MAY 16, 2024

The need-to-know this morning Biogen  and  Ionis Pharmaceuticals  are  ending their development  of an experimental drug for ALS based on results of a Phase 1/2 trial. Novartis  said it’s  met all tender offer conditions  to acquire German biotech Morphosys.

Immunity 264

Immunity Immunization Drug Pricing Drug Development 264

Pharmaceutical Technology

OCTOBER 25, 2022

BioMed X has entered a research partnership with Sanofi to leverage artificial intelligence (AI) for drug development. This team will focus on creating a versatile computational platform that can precisely forecast the first-in-class drug candidates’ efficacy in virtual patient groups.

Drug Development 98

Drug Development Diabetes Immunization Immunity 98

BioPharma Dive

AUGUST 22, 2023

Billing itself as both a scientific and investment partner, Foundery aims to provide research grants and drug development support to researchers developing new immunotherapies.

Immunity 98

Immunity Immunization Drug Development 98

pharmaphorum

DECEMBER 4, 2020

The 4 th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. This is the industry’s definitive antigen specific drug development forum.

Immunity 52

Immunity Immunization Medical Schools Drug Development 52

STAT

OCTOBER 24, 2024

Among the basic and life-saving medicines for which shortages continue to be problematic are Rho(D) immune globulin, pain and sedation medications, and ADHD pills. So far this year, 95 new shortages were reported, a drop from 156 in 2023, although 50% of active shortages have persisted for two or more years.

Immunity 261

Immunity Immunization Drug Pricing Drug Development 261

pharmaphorum

OCTOBER 13, 2021

The Gastrointestinal Cancer Drug Development Summit is the only biopharma-led conference dedicated to identifying and progressing therapeutic opportunities in targeted and immunotherapies, ADCs, and precision oncology to address the large unmet clinical need in GI cancers. Register for your FREE ticket here: [link].

Drug Development 52

Drug Development Immunity Immunization 52

BioPharma Dive

APRIL 10, 2024

The biotech is working on a preventive therapy for the immune disorder, known as FNAIT for short, while J&J is studying its drug nipocalimab as a treatment.

Drug Development 60

Drug Development Immunity Immunization 60

pharmaphorum

OCTOBER 17, 2022

When James P Allison and Tasuku Honjo were awarded the Nobel Prize for Medicine in 2018 for their discovery of cancer therapy through inhibition of negative immune regulation, it shone a light on decades of research into recruiting the immune system to fight cancer. That’s what makes them such a tricky detective mystery!

Immunity 115

Immunity Immunization Drug Development 115

pharmaphorum

MARCH 10, 2022

With a tight lens on late translational through to phase II clinical progress; the 2nd Chronic HBV Drug Development Summit is dedicated to advancing direct antiviral and immunotherapy pipelines in combination therapy paradigms. The post Welcome to the 2nd Chronic HBV Drug Development Summit appeared first on.

Drug Development 52

Drug Development Immunization Immunity Vaccines 52

pharmaphorum

APRIL 20, 2021

The Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit is the definitive industry-led forum for drug development in the largest solid tumor indication. The post Non-Small Cell Lung Cancer Drug Development Summit appeared first on. View the event guide now for more details!

Drug Development 52

Drug Development Medical Schools Immunization Immunity 52

pharmaphorum

SEPTEMBER 16, 2022

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. It also bodes well for improving clinical trial success rates.

Immunity 135

Immunity Immunization Drug Development 135

European Pharmaceutical Review

MAY 14, 2024

Takeda and AC Immune SA have agreed a global option and license agreement for a potential first-in-class Abeta-targeting active immunotherapy for Alzheimer’s. AC Immune’s related immunotherapies targeting Abeta are part of the deal, including the Alzheimer’s treatment ACI-24.060.

Immunity 97

Immunity Immunization Drug Development 97

Pharmaceutical Technology

APRIL 5, 2023

Absci stated that this collaboration combines AI drug creation technology and oncology bioinformatics, thereby reducing the time and cost of cancer drug development. Initially, the company will use its reverse immunology technology to search the database for antibodies from patients showing strong immune responses.

Drug Development 52

Drug Development Immunity Immunization 52

BioPharma Dive

OCTOBER 10, 2024

The offering will fund testing of a potential rival to Amgen’s Tezspire and is already the sixth for an immune drug developer this year, the most since 2021.

Immunity 69

Immunity Immunization Drug Development 69

pharmaphorum

AUGUST 5, 2022

MiroBio was formed in 2019 to develop checkpoint agonist antibodies for autoimmune and inflammatory disorders that can be used to apply the “natural brakes” of the immune system. 7 integrin, with three candidates in early-stage clinical development.

Immunity 105

Immunity Immunization Drug Development 105

BioPharma Dive

OCTOBER 31, 2024

The immune disease drug developer expects to raise $300 million in a private financing set to close before its combination with the struggling Aerovate.

Immunity 64

Immunity Immunization Drug Development 64

BioPharma Dive

OCTOBER 10, 2024

The offering will fund testing of a potential rival to Amgen’s Tezpire and is already the sixth for an immune drug developer this year, the most since 2021.

Immunity 64

Immunity Immunization Drug Development 64

STAT

MARCH 6, 2023

“I’m slowly running out of options,” said Young, 62, who in November began   receiving   a five-month series of shots at a clinic near her San Francisco home; the vaccine is designed to teach her immune cells to recognize and combat tumors.

Vaccines 246

Vaccines Bioethics Immunity Immunization 246

Pharmaceutical Technology

MARCH 2, 2023

Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Immunity 40

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 40

pharmaphorum

NOVEMBER 30, 2020

As AAV is a virus derived from the common cold, the immune system can easily have levels of pre-existing NAbs that will recognise and neutralise AAV, rendering it ineffective. In serious cases, higher levels of pre-existing NAbs can even cause a dangerous immune reaction when such therapies are administered.

Immunity 105

Immunity Immunization Drug Development 105

pharmaphorum

JANUARY 10, 2023

Astellas has licensed rights to a drug developed by Selecta Biosciences that could make more patients eligible for treatment with its gene therapy for inherited neuromuscular disorder Pompe disease.

Immunity 119

Immunity Immunization Drug Development 119

European Pharmaceutical Review

JANUARY 4, 2024

Immunotherapy drugs like teclistamab can result in potentially fatal side effects, including CRS and immune cell-associated neurotoxicity syndrome (ICANS). An overactive immune response [is] the hallmark of CRS,” Landgren added. The drug tocilizumab for example, has been used historically to treat CRS from immunotherapies.

Immunity 97

Immunity Immunization Hospitals Drug Development 97

Pharmaceutical Technology

JUNE 12, 2023

CB1 is predominantly found in the central and peripheral nervous system, whereas CB2 is primarily located in immune cells. As drug targets, these receptors have demonstrated therapeutic value against different pain varieties. However, along with other painkiller alternatives, doubts have been cast over their efficacy.

Immunity 143

Immunity Immunization Drug Development 143

Pharmaceutical Technology

MAY 22, 2023

It can suppress Th2 immune responses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s). The acceptance of the IND application for SM17 not only accelerated the company’s clinical development project for the treatment of asthma indications in China, but also demonstrated the high efficiency of our new drug development. “It

Immunity 109

Immunity Immunization Drug Development 109